Gooderham Melinda, Lynde Charles W, Papp Kim, Bourcier Marc, Guenther Lyn, Gulliver Wayne, Hong Chih-Ho, Poulin Yves, Sussman Gordon, Vender Ronald
1 Queen's University, SKiN Centre for Dermatology, and Probity Medical Research, Peterborough, ON, Canada.
2 Lynde Dermatology, Probity Medical Research, Markham Ontario, and Department of Medicine, University of Toronto, Toronto, ON, Canada.
J Cutan Med Surg. 2017 Jan/Feb;21(1):31-39. doi: 10.1177/1203475416670364. Epub 2016 Sep 22.
Atopic dermatitis (AD) is a chronic, pruritic inflammatory skin disease resulting from defects in skin barrier and aberrant immune responses. AD significantly affects the quality of life. Not all patients respond to topical therapies, and often systemic therapy is required to control the disease.
To review the treatment options for adult AD patients including those options for patients who do not respond adequately or have contraindications to oral systemic therapy.
A working group of clinicians with experience managing AD was convened to review the current literature on treatment options for adult AD patients. This review is based on the best available evidence from a published systematic review and an additional literature search.
Current treatments for AD are reviewed, including options for adult AD patients who do not respond or have contraindications to current systemic therapies. A new approach with targeted therapies is reviewed based on best available evidence.
Many AD patients respond satisfactorily to topical or systemic treatments, but for those patients who do not respond or have contraindications, new biologic agents appear to be promising therapies.
特应性皮炎（AD）是一种慢性、瘙痒性炎症性皮肤病，由皮肤屏障缺陷和异常免疫反应引起。AD显著影响生活质量。并非所有患者对局部治疗都有反应，通常需要全身治疗来控制疾病。
回顾成人AD患者的治疗选择，包括对口服全身治疗反应不佳或有禁忌证的患者的治疗选择。
召集一组有AD管理经验的临床医生组成工作组，回顾关于成人AD患者治疗选择的当前文献。本综述基于已发表的系统评价和额外文献检索中的最佳现有证据。
回顾了AD的当前治疗方法，包括对当前全身治疗无反应或有禁忌证的成人AD患者的治疗选择。基于最佳现有证据，回顾了一种靶向治疗的新方法。
许多AD患者对局部或全身治疗反应良好，但对于那些无反应或有禁忌证的患者，新的生物制剂似乎是有前景的治疗方法。
